Alabama is currently home to 1230 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
Recruiting
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
12/02/2024
Locations: University of Alabama, Children's Alabama, Birmingham, Alabama
Conditions: High-risk Neuroblastoma
Register for Updates
Vincristine Pharmacokinetics in Infants
NCT05359237
Recruiting
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence... Read More
Gender:
ALL
Ages:
12 years and below
Trial Updated:
12/02/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05559879
Recruiting
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
Register for Updates
Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
NCT04920136
Recruiting
This study is to compare the two techniques to achieve change in the tissue quality at areas of lack of Keratinized Tissue (KT) using soft tissue grafting with autogenous graft material (Free Gingival Graft)(FGG) vs Strip gingival graft with acellular dermal matrix (ADM) (SGG+ADM).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/26/2024
Locations: Unversity of Alabama at Birmingham, School of Dentistry, Birmingham, Alabama
Conditions: Gingival Recession, Lack of Keratinized Attached Peri-implant Mucosa, Thin Gingiva
Register for Updates
Relationships of Affect and Neuroinflammation With Clinical Pain in Veterans With Fibromyalgia
NCT06574165
Recruiting
Fibromyalgia (FM) is a chronic pain condition that disproportionately impacts Veterans. Individuals diagnosed with FM patients experience lower self-esteem and positive affect, as well as greater levels of depression, anxiety, negative affect, and pain catastrophizing. Among those experiencing FM, clinical and experimental pain are associated with specific dispositional trait profiles, which are indexed by levels of negative affect and positive affect. Neuroinflammation and inflammation also pla... Read More
Gender:
ALL
Ages:
Between 19 years and 85 years
Trial Updated:
11/25/2024
Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
Conditions: Fibromyalgia
Register for Updates
Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD
NCT06169852
Recruiting
Our goal is to better understand how DBS modifies local neuronal activity and to pioneer device technologies that can record local DBS-evoked potentials (DLEPs) to guide therapy. Our vision is for a patient's unique electrophysiology to guide both electrode targeting during surgery and programming in clinic, eventually as an integrated component of the implanted pulse generator. Our results will inform directional DBS for PD and serve as a model for translation to other diseases where knowledge... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
11/25/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114
Recruiting
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University Of South Alabama, Mobile, Alabama
Conditions: Sickle Cell Disease
Register for Updates
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
NCT04991103
Recruiting
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
Register for Updates
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures At High Risk of Infection: TOBRA
NCT04597008
Recruiting
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/25/2024
Locations: University of Alabama Heersink School of Medicine, Birmingham, Alabama
Conditions: Post Operative Surgical Site Infection
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Research Site, Daphne, Alabama
Conditions: Breast Cancer
Register for Updates
A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications.
NCT05568706
Recruiting
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Longwood Research, Huntsville, Alabama
Conditions: RSV Infection
Register for Updates